Mark Coleman, who serves as a director at Axsome Therapeutics, Inc., recently engaged in substantial insider selling. According to filings with the Securities and Exchange Commission (SEC), Mr. Coleman sold a combined total of 17,537 shares of common stock, representing an aggregate value of approximately $4.02 million. These transactions were spread across several days, concluding by June 2, 2026.
The insider divestiture occurred against the backdrop of strong market performance for Axsome Therapeutics (NASDAQ: AXSM). The stock was trading near its 52-week high of $238.56 and had achieved a notable 106% return over the previous year. Despite this positive momentum, analysis from InvestingPro suggests that the stock may be undervalued at current price levels, indicating strong market belief in the company despite recent revisions to analyst earnings.
Details of the Stock Sales
The sales were meticulously structured and took place between May 29, 2026, and June 2, 2026. Crucially, these shares did not represent open market purchases but rather underlying stock derived from previously exercised options, sold pursuant to a pre-approved Rule 10b5-1 trading plan. This structure is designed to execute trades without suggesting immediate knowledge of non-public information.
- May 29, 2026: Mr. Coleman sold 6,000 shares at a weighted average price of $233.46 per share. The specific sale prices for this block ranged from $231.50 to $235.23.
- June 1, 2026: A second tranche of 6,000 shares was sold at a weighted average price of $230.30 per share. Individual transaction prices for this sale fell between $229.56 and $232.14.
- June 2, 2026: The final reported sale involved 5,537 shares at a weighted average price of $223.39 per share. This block saw prices ranging from $221.82 to $225.21.
Following these disclosed transactions, the record shows that Mark Coleman directly retains ownership of 29,603 shares of Axsome Therapeutics common stock. Furthermore, his indirect beneficial ownership is noted at 403,856 shares held by an entity over which he maintains both voting and dispositive power.
Company Financial Updates and Community Focus
In other recent corporate news, Axsome Therapeutics released its financial results for the first quarter of 2026. The company reported a net loss of $1.26 per share. This figure represented a substantial increase compared to the previously anticipated net loss of $0.83 per share, signaling an earnings miss.
For revenue, Axsome recorded $191.2 million for the quarter. This amount was slightly below the expected revenue target of $193.46 million. Beyond these financial disclosures, the company is actively participating in community awareness initiatives. Specifically, Axsome Therapeutics announced its support for the inaugural Headache in the City educational campaign, which is organized by the Headache Alliance in New York City and falls under Migraine and Headache Awareness Month.
As part of this commitment to raising health consciousness, Axsome’s corporate headquarters located at One World Trade Center will be illuminated in purple. This specific measure utilizes the Spireworks program to draw attention to migraine conditions, underscoring a blend of financial activity with community engagement efforts.
Market Context and Analyst View
The current market data for Axsome Therapeutics shows the stock closed at 222.10, reflecting a decline of $0.06 or 0.03% on that day. The trading activity provides context against recent performance metrics, including the strong momentum noted by various analysis tools.
Key Takeaways and Market Implications
- Insider Selling Under a Plan: The $4.02 million sale by director Mark Coleman was executed through a Rule 10b5-1 trading plan, which is a structured mechanism intended to remove the implication of immediate or non-public information influencing the sales timing.
- Valuation Discrepancy: Despite the insider selling and recent earnings miss (Q1 net loss of $1.26 per share vs. anticipated $0.83), external analysis suggests the stock may remain undervalued, maintaining strong momentum despite analyst revisions.
- Operational Focus Beyond Finance: The company is visibly engaging in community health initiatives, such as supporting Migraine and Headache Awareness Month events and illuminating its headquarters in purple to raise public awareness for migraine conditions.
Risks and Uncertainties
Several factors present uncertainties regarding the stock's trajectory. The most explicit financial risk noted is the earnings miss in Q1 2026, where the net loss per share was $1.26, significantly exceeding the expected loss of $0.83. Furthermore, while the company has achieved a remarkable return over the past year, the recent sales by key directors introduce questions regarding internal valuation perceptions at various price points.